Answers are grounded in this paper and cite their sources.
Transition to dolutegravir among 21 167 individuals experienced in antiretroviral therapy in West Africa showed heterogeneous timelines and patterns. Initially reported sex disparities tended to catch up over time with persisting disparities, according to contributing HIV clinics. Key factors facilitating dolutegravir switch were male sex, age <50 years, viral suppression, and regimens not based on protease inhibitors.
No takes yet. Share an insight, caveat, or question.
Tiendrebeogo et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: